Glen A Kennedy

Summary

Country: Australia

Publications

  1. ncbi Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease
    G A Kennedy
    Department of Haematology, Royal Brisbane and Women s Hospital, Brisbane, Queensland 4029, Australia
    Bone Marrow Transplant 37:1143-7. 2006
  2. ncbi Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review
    Glen A Kennedy
    Department of Haematology, Royal Brisbane Hospital, Australia
    Br J Haematol 119:412-6. 2002
  3. ncbi Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange
    G A Kennedy
    Department of Haematology, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Bone Marrow Transplant 45:699-704. 2010
  4. ncbi Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria
    Glen A Kennedy
    Department of Haematology, Royal Brisbane and Women s Hospital, Herston, Queensland, Australia
    Transfusion 49:1884-9. 2009
  5. ncbi Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience
    G A Kennedy
    Division of Oncology, Royal Brisbane and Women s Hospital, Queensland, Australia
    Clin Lab Haematol 28:189-97. 2006
  6. ncbi Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases
    Glen A Kennedy
    Department of Haematology, Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Brisbane, Queensland, Australia
    Pathology 34:263-6. 2002
  7. ncbi Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange
    Cameron Curley
    Department of Haematology, Royal Brisbane and Women s Hospital, Brisbane, Australia
    Transfusion 52:291-7. 2012
  8. ncbi Identification of tumours with the CD43 only phenotype during the investigation of suspected lymphoma: a heterogeneous group not necessarily of T cell origin
    Glen A Kennedy
    Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
    Pathology 34:46-50. 2002
  9. ncbi A novel mutation of the erythropoietin receptor gene associated with primary familial and congenital polycythaemia
    Kacey O'Rourke
    Department of Haematology, Royal Brisbane and Women s Hospital, Butterfield St, Herston, QLD, 4029, Australia
    Int J Hematol 93:542-4. 2011
  10. ncbi Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases
    Glen A Kennedy
    Haematology Service, Peter MacCallum Cancer Centre, St Vincent's Hospital, Melbourne, Victoria, Australia
    Australas J Dermatol 45:34-7. 2004

Collaborators

Detail Information

Publications11

  1. ncbi Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease
    G A Kennedy
    Department of Haematology, Royal Brisbane and Women s Hospital, Brisbane, Queensland 4029, Australia
    Bone Marrow Transplant 37:1143-7. 2006
    ..Further study of this immunosuppression combination in a larger cohort of patients in this setting is indicated...
  2. ncbi Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review
    Glen A Kennedy
    Department of Haematology, Royal Brisbane Hospital, Australia
    Br J Haematol 119:412-6. 2002
    ..As such, repeat tissue biopsy should be undertaken to document CD20 expression by both flow cytometry and immunohistochemistry prior to considering repeated courses of rituximab in relapsed aggressive lymphomas...
  3. ncbi Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange
    G A Kennedy
    Department of Haematology, Royal Brisbane and Women s Hospital, Brisbane, Queensland, Australia
    Bone Marrow Transplant 45:699-704. 2010
    ..PE is potentially efficacious in the absence of active acute GVHD, and ineffective when acute GVHD is manifest...
  4. ncbi Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria
    Glen A Kennedy
    Department of Haematology, Royal Brisbane and Women s Hospital, Herston, Queensland, Australia
    Transfusion 49:1884-9. 2009
    ..However, both newly proposed criteria are yet to be clinically validated...
  5. ncbi Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience
    G A Kennedy
    Division of Oncology, Royal Brisbane and Women s Hospital, Queensland, Australia
    Clin Lab Haematol 28:189-97. 2006
    ..Efforts should continue on alternative allogeneic SCT approaches to reduce the high early TRM rate associated with myeloablative conditioning...
  6. ncbi Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases
    Glen A Kennedy
    Department of Haematology, Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Brisbane, Queensland, Australia
    Pathology 34:263-6. 2002
    ..We present a further five cases of MMF-related dysgranulopoiesis characterised by a pseudo-PH anomaly occurring after renal transplantation...
  7. ncbi Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange
    Cameron Curley
    Department of Haematology, Royal Brisbane and Women s Hospital, Brisbane, Australia
    Transfusion 52:291-7. 2012
    ..Although pretransplant (recipient) isoagglutinin reduction may be associated with decreased immunohematologic complications in this setting, there is no consensus with respect to strategies for isoagglutinin reduction...
  8. ncbi Identification of tumours with the CD43 only phenotype during the investigation of suspected lymphoma: a heterogeneous group not necessarily of T cell origin
    Glen A Kennedy
    Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
    Pathology 34:46-50. 2002
    ..In this setting, tumours expressing CD43 in the absence of other T or B cell markers (CD43 only phenotype) are rare. We present four cases with this aberrant phenotype seen at our institution...
  9. ncbi A novel mutation of the erythropoietin receptor gene associated with primary familial and congenital polycythaemia
    Kacey O'Rourke
    Department of Haematology, Royal Brisbane and Women s Hospital, Butterfield St, Herston, QLD, 4029, Australia
    Int J Hematol 93:542-4. 2011
    ..Given the strong family history of complications attributable to erythrocytosis we have recommended venesection with a haematocrit target of ≤0.45 for our patient...
  10. ncbi Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases
    Glen A Kennedy
    Haematology Service, Peter MacCallum Cancer Centre, St Vincent's Hospital, Melbourne, Victoria, Australia
    Australas J Dermatol 45:34-7. 2004
    ..No adverse effects were observed. To date, disease progression has occurred in one case during overall follow up at 6 and 17 months. The potential role of rituximab in the treatment of these lymphomas is discussed...
  11. ncbi Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia
    Fiona Chionh
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    Leuk Lymphoma 46:603-5. 2005
    ..Thus, in patients with hematological malignancies who develop significant gastrointestinal symptoms, we recommend that endoscopic investigations and biopsies are performed to exclude IA as a potential cause...